z-logo
Premium
Non‐T, non‐B childhood acute lymphoblastic leukemia. Correlation between cytochemical markers and first complete remission
Author(s) -
Basso Giuseppe,
Agostini Carlo,
Cocito Maria G.,
Pezzutto Antonio,
Destro Roberta,
Capuzzo Fabrizia,
Gazzola Maria V.,
Raimondi Roberto,
Zanesco Luigi,
Semenzato Giampietro
Publication year - 1984
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19840915)54:6<981::aid-cncr2820540606>3.0.co;2-y
Subject(s) - acid phosphatase , lymphoblastic leukemia , complete remission , medicine , esterase , enzyme , gastroenterology , leukemia , pathology , immunology , biology , biochemistry , chemotherapy
Abstract The positivity for four cytochemical reactions, acid phosphatase (AcP), alpha‐naphtyl acid acetate esterase (ANAE), beta‐glucuronidase (BG), and N‐acetyl beta‐glucosaminidase (NABG) was correlated to first remission duration in 120 children affected with non‐T, non‐B acute lymphoblastic leukemia (ALL). The percentages of patients remaining in complete remission at 72 months were always higher for children whose blasts lacked these enzymatic reactions; however, a statistical difference was found only between BG + and BG − ALL. It also appears that more complete enzymatic patterns of leukemic cells are associated with a poorer prognosis. The percentage of patients still in their first remission was 89% for leukemias with no cytochemical markers, 59% when one reaction was present, but less than 39% when two or more enzymes were detected in the blasts. It is noteworthy that the blasts of patients with more severe prognosis demonstrated a simultaneous positivity for AcP–ANAE or BG–NABG cytochemical reactions. The possible usefulness of these cytochemical markers to detect subsets of patients with different prognostic significance among non‐T, non‐B ALL is discussed.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here